Restoring the gut: VE303’s strategy for C. diff relief
A new publication in Nature Medicine highlights the potential of VE303 for preventing recurrent C. difficile infection, detailing its impact on the gut microbiome and immune response.
List view / Grid view
A new publication in Nature Medicine highlights the potential of VE303 for preventing recurrent C. difficile infection, detailing its impact on the gut microbiome and immune response.
New cell therapy, Cilta-cel, shows promise in the treatment of multiple myeloma, providing a personalised approach with the potential for long-term remission.
Rigel Pharmaceuticals has announced the enrolment of the first patient in a Phase I trial evaluating fostamatinib for sickle cell disease.
Cancer Research UK, Cytovation, and the Norwegian Cancer Society have teamed up to advance the treatment of adrenocortical carcinoma (ACC). The collaboration will support the Phase II clinical trial of Cytovation’s innovative therapy, CY-101.
Researchers at the University of Virginia School of Medicine have developed computer models to create more targeted antibiotics. This approach aims to fight antibiotic resistance by focusing on specific bacteria in different parts of the body, reducing the reliance on broad-spectrum antibiotics.
Explore how FDA’s Project Optimus is reshaping oncology drug dosing strategies, with insights on precision medicine, adaptive trial designs, and the role of CROs in optimising patient outcomes.
Researchers have identified early molecular changes in Rett syndrome that could lead to improved treatments for the condition.
Macrocycles outperform traditional therapeutics on several fronts, yet they account for just four percent of FDA-approved drugs. Colleagues Ann E Cleves and Ajay N Jain from Optibrium Ltd explain why we can expect to see this number increase in the coming years.
UVA Center for Diabetes Technology and Tandem Diabetes Care partner to advance automated insulin delivery systems for diabetes management.
LB Pharmaceuticals announced positive Phase II results for LB-102, showing significant symptom improvement in schizophrenia with a favourable safety profile.
In part two of the step-by-step scientific workflow for drug discovery series, Dr Raminderpal Singh and Nina Truter describe the functions of the workflow previously outlined and include key considerations.
Learn how Kindeva and Emervax are advancing vaccine delivery with painless, needle-free technology designed to improve accessibility and uptake worldwide.
9 January 2025 | By Eurofins DiscoverX
Gain valuable insights into the latest advancements in obesity drug discovery and enhance your research capabilities.
Researchers at the Medical University of South Carolina have discovered a key genetic mechanism that could lead to RNA-based therapies for psychiatric disorders triggered by emotional experiences.
Researchers at Washington University are developing a vaccine using nanofiber technology to prevent dementia, offering a safer and more effective alternative to current treatments.